Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciences's revenue per share for the
three
months ended in Jun. 2026 was $4.77.
Pacira BioSciences's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $17.73.
During the past 12 months, the average Revenue Per Share Growth Rate of Pacira BioSciences was 15.70% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 4.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 9.30% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 10.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Pacira BioSciences's Revenue per Share or its related term are showing as below:
PCRX'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -66.9 Med: 11 Max: 80.4
Current: 4
During the past 13 years, Pacira BioSciences's highest 3-Year average Revenue Per Share Growth Rate was 80.40% per year. The lowest was -66.90% per year. And the median was 11.00% per year.
PCRX's 3-Year Revenue Growth Rate is ranked better than 50.88% of 904
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs PCRX: 4.00
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Pacira BioSciences Revenue per Share Related Terms
Pacira BioSciences Revenue per Share Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCRX vs AMPH, COLL, IRWD: Revenue per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Pacira BioSciences's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (PCRX) has a Revenue per Share of $17.73 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Pacira BioSciences and its competitors. According to the industry distribution chart, Pacira BioSciences ranks #444 out of 904 companies in the Drug Manufacturers industry, placing it in the top 49.1%.
Is Pacira BioSciences' Revenue per Share too high?
Pacira BioSciences' current Revenue per Share is $17.73. The Drug Manufacturers industry median Revenue per Share is 3.70. Pacira BioSciences' value of $17.73 is 379.2% above this industry median. Based on the distribution chart, Pacira BioSciences ranks #444 out of 904 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Revenue per Share compare to AMPH and COLL?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #444 out of 904 companies for Revenue per Share. This puts Pacira BioSciences in the upper half of its industry. The industry median Revenue per Share is 3.70. Pacira BioSciences' value of $17.73 is 379.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.70, based on 904 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Revenue per Share of $17.73 is 379.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Revenue per Share is $17.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.31, compared to a current price of $25.64 — trading 12.5% below its estimated fair value. The current Revenue per Share is $17.73 and 379.2% above the Drug Manufacturers industry median of 3.70. Pacira BioSciences' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Revenue per Share is $17.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (PCRX) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of $25.64 is trading 12.5% below its estimated GF Value™ of $29.31.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for PCRX:
Revenue per Share: $17.73
GF Value™: $29.31 vs. price of $25.64 (12.5% below fair value)
Industry Position: 379.2% above the Drug Manufacturers median (#444 of 904)
No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
80GF Score
Get the complete analysis for PCRX
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCRX has been successfully added to your 
